PureTech Health PLC (PRTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PureTech Health PLC (PRTC) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.47 Million) by net assets ($305.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is PureTech Health PLC worth for the company's overall valuation and market capitalisation.
PureTech Health PLC - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PureTech Health PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PureTech Health PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PureTech Health PLC ranked by their cash flow conversion efficiency. Explore PRTC operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
-0.010x |
|
Salmones Camanchaca S.A
SN:SALMOCAM
|
-0.019x |
|
Regulus Resources Inc
V:REG
|
-0.007x |
|
Codere Online US Corp
NASDAQ:CDRO
|
0.135x |
|
Shanghai Jiaoda Onlly Co Ltd
SHG:600530
|
0.031x |
|
Jiangxi Selon Industrial Co Ltd
SHE:002748
|
-0.009x |
|
WEIMOB INC. DL-0001
F:36W
|
-0.130x |
|
63 moons technologies limited
NSE:63MOONS
|
-0.037x |
Annual Cash Flow Conversion Efficiency for PureTech Health PLC (2012–2025)
The table below shows the annual cash flow conversion efficiency of PureTech Health PLC from 2012 to 2025. View PureTech Health PLC share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.68 Million | $-85.33 Million | -0.279x | +15.25% |
| 2024-12-31 | $407.93 Million | $-134.37 Million | -0.329x | -42.50% |
| 2023-12-31 | $458.23 Million | $-105.92 Million | -0.231x | +29.21% |
| 2022-12-31 | $547.59 Million | $-178.79 Million | -0.327x | -20.51% |
| 2021-12-31 | $584.15 Million | $-158.27 Million | -0.271x | -34.32% |
| 2020-12-31 | $653.54 Million | $-131.83 Million | -0.202x | -33.66% |
| 2019-12-31 | $650.40 Million | $-98.16 Million | -0.151x | +65.38% |
| 2018-12-31 | $166.97 Million | $-72.80 Million | -0.436x | +68.54% |
| 2017-12-31 | $64.00 Million | $-88.69 Million | -1.386x | -120.68% |
| 2016-12-31 | $92.41 Million | $-58.03 Million | -0.628x | -260.08% |
| 2015-12-31 | $164.05 Million | $-28.61 Million | -0.174x | -121.14% |
| 2014-12-31 | $133.69 Million | $-10.54 Million | -0.079x | -107.21% |
| 2013-12-31 | $-8.03 Million | $-8.77 Million | 1.093x | +152.49% |
| 2012-12-31 | $-3.35 Million | $-1.45 Million | 0.433x | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more